Summary. Increased expression of Fas receptor by haemopoietic progenitors in aplastic anaemia (AA) suggests that excessive apoptosis contributes to multilineage bone marrow (BM) failure. To investigate the role of Fas ligand (FasL) in triggering progenitor cell death, we examined FasL levels in T lymphocytes of patients with severe untreated AA (n 8). Expression of FasL on the surface of CD3 1 cells was not detectable. However, flow cytometric analysis of saponin-permeabilized cells demonstrated higher levels of intracellular FasL in AA than in normal T cells (P , 0´005), both prior to and following activation with phytohaemagglutinin. Confocal microscopy revealed that FasL-specific signals overlapped with cathepsin D staining, indicating that intracellular FasL is stored in lysosomal granules. Levels of intracellular FasL in patients examined 1 month after immunosuppression with antilymphocyte globulin and cyclosporin A were lower than prior to treatment. The caspase inhibitors, DEVD and zVAD, enhanced colony formation and prolonged survival of AA BM cells in liquid cultures by about 10-fold (P , 0´05). Taken together, these data provide further evidence that apoptosis by the Fas/FasL system plays a role in the depletion of stem cells in AA.
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T cell-mediated suppression of haemopoiesis is considered the most important pathogenic mechanism of bone marrow (BM) failure in aplastic anaemia (AA). Clinical evidence is provided by the effectiveness of immunosuppressive treatment with antilymphocyte globulin (ALG) and cyclosporin A (CsA) (Young, 1996) . The proportion of cytotoxic T lymphocytes in AA is increased above normal levels (Maciejewski et al, 1994) and T-cell clones capable of killing autologous haemopoietic progenitors have been isolated from patients' BM (Nakao et al, 1997) . It has been postulated that T cells play a role in BM destruction by overproducing interferon gamma (IFN-g) and tumour necrosis factor alpha (TNF-a) (Zoumbos et al, 1985; Nakao et al, 1992) , both cytokines known as potent inhibitors of haemopoiesis (Takahashi et al, 1990) . Their effect may be exerted in part by induction of Fas antigen expression, a cell-surface receptor that mediates apoptotic cell death (Maciejewski et al, 1995a; Nagafuji et al, 1995) . Indeed, CD34
1 progenitors in AA express abnormally high levels of Fas (Maciejewski et al, 1995b) , and patients' BM contains a significantly greater proportion of apoptotic cells than observed in healthy controls (Philpott et al, 1995; Callera & Falcao, 1997) .
Fas-dependent apoptotic cell death is triggered by Fas ligand (FasL) (Suda & Nagata, 1994) . The signalling cascade involves activation of cysteine proteases, termed caspases, which cleave and activate signalling molecules including nuclear enzymes participating in degradation of DNA to oligonucleosomal fragments (Cohen, 1997) . FasL is a type II transmembrane protein of the TNF family, predominantly expressed in activated T cells and natural killer (NK) cells (Suda & Nagata, 1994) . It has recently been demonstrated that newly synthesized FasL is stored in secretory lysosomes and that degranulation controls its delivery to the surface of T and NK cells upon target cell recognition (Bossi & Griffiths, 1999) . Membrane-bound FasL is converted to a soluble form by a matrix metalloproteinase, resembling the enzyme involved in cleavage of TNF-a. Efficient killing is triggered by the membrane-bound FasL, while shedding soluble FasL from the membrane downregulates its cytotoxic activity (Tanaka et al, 1998) .
Fas/FasL interactions play an important role in the regulation of homeostasis of the immune system, including clonal T-cell selection, protection of immune privileged sites, and antiviral and antitumour defence (Nagata & Golstein, cause tissue destruction in hepatitis, insulin-dependent diabetes and thyroiditis (French & Tschopp, 1997) . The role of apoptosis in diseases of the haemopoietic system is less well defined. In multiple myeloma, expression of FasL on the surface of neoplastic plasma cells has been postulated as a mechanism of tumour escape from immune surveillance (Villunger et al, 1997) . In myelodysplastic syndromes, excessive intramedullary death of haemopoietic progenitors appears to result from upregulation of Fas and FasL on CD34 1 cells and lymphocytes respectively (Gupta et al, 1999) .
We have studied expression of FasL in T cells from AA patients. Levels of intracellular FasL in AA cells analysed ex vivo and following phytohaemagglutinin (PHA) activation were increased compared with normal controls. Inhibitors of caspases, applied to interfere with the apoptotic pathway, prolonged survival of clonogenic AA progenitors in vitro.
Our results indicate that intracellular FasL, found in T cells at abnormally high levels, may be responsible for Fasmediated apoptosis of haemopoietic progenitors in AA.
PATIENTS AND METHODS
Patients and controls. Nine patients were analysed at diagnosis of severe idiopathic AA. All patients presented with untreated disease, hypoplastic BM and low peripheral blood (PB) cell values, and were transfusion dependent. Eight patients were analysed within the first month, and six patients at 2±12 years after immunosuppressive treatment with ALG and CsA. Control PB and BM was obtained from 10 healthy donors. The study was approved by the Ethical Committee of the University Hospitals Basel.
Cells. Mononuclear cells (MNCs) were isolated from PB or BM by Ficoll-Hypaque (Sigma, St. Louis, Missouri) density gradient centrifugation (d 1´077). T cells were purified by negative selection using super-paramagnetic MACS microbeads (Milteny Biotech, Auburn, CA, USA). Briefly, MNCs were washed and incubated with a mixture of lineage-specific monoclonal antibodies (mAbs; anti-CD11b, CD16, CD19, CD36, CD56) followed by incubation with magnetic beads coupled to goat antimouse antibody (Ab). After magnetic separation, purity of T cells collected in the negative fraction was . 98%. T cells were seeded at 1 Â 10 6 /ml in 5 ml of Iscove's modified Dulbecco medium (IMDM; Gibco, Gaithersburg, MD, USA) containing 1% Nutridoma SP (Bo Èehringer Mannheim, Mannheim, Germany) without serum addition. PHA (Murex, Dartford, England) was used at 5 mg/ml. After 3 d, viable cells were recovered by density centrifugation on Ficoll-Hypaque and used for intracellular FACS analysis.
FACS analysis for FasL. For analysis of membrane-bound FasL, 2 Â 10 5 MNCs were incubated for 30 min with 20 mg/ml mouse anti-human FasL NOK-1 mAb (Pharmingen, San Diego, CA, USA), washed twice in phosphatebuffered saline (PBS) with 0´5% bovine serum albumin (BSA), followed by 30 min with goat anti-mouse fluorescein isothiocyanate (FITC)-labelled IgG (Jackson Laboratories, West Grove, PA, USA). As a positive control, MNCs activated for 3 h with phorbol 12-myristate13-acetate (PMA; Sigma) at 20 ng/ml and calcium ionophore (Calbiochem, La Jolla, CA, USA) at 1 mg/ml in the presence of 10 mmol/l BB3103 (British Biotech, Oxford, UK) were used. For analysis of intracellular FasL, 2 Â 10 5 MNCs or T cells were fixed in 2% paraformaldehyde and permeabilized for 20 min in PBS containing 0´5% BSA and 0´1% saponin. Cells were incubated for 30 min with 20 mg/ml mouse anti-human FasL NOK-1 mAb or 0´5 mg/ml rabbit anti-human FasL N20 Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by goat anti-mouse or goat anti-rabbit FITClabelled IgG (Jackson Laboratories). In all analyses of MNCs, a double staining with mouse anti-human CD3 phycoerythrin (PE)-labelled IgG1 (Becton Dickinson, San Jose Â, CA, USA) was performed. For negative control stainings, mouse IgG1 (Pharmingen) followed by goat anti-mouse FITC or goat anti-rabbit-FITC, and mouse IgG1-PE (Becton Dickinson) were used. At least 10 000 events were acquired on a FACScan and analysed using cellquest software (Becton Dickinson).
Confocal analysis. Analysis was performed as described previously (Chklovskaia et al, 1999) . T cells were allowed to settle onto poly l-lysine-coated coverslips (Sigma Diagnostics), fixed with 4% paraformaldehyde and permeabilized with 0´1% saponin. Unspecific staining was blocked with 0´5% sodium borohydride (Merck, Darmstadt, Germany) and 5% goat serum. Cells were incubated for 1 h at room temperature with 20 mg/ml NOK-1 mAb or 1 mg/ml N20 Ab and an Ab against cathepsin D (rabbit IgG, gift from Lukas Landmann, Institute of Anatomy, Basel University, Basel, Switzerland), followed by goat anti-mouse IgG or goat anti-rabbit IgG conjugated with FITC or Texas Red (TxR; all from Jackson Laboratories). Slides were mounted using Mowiol (Hoechst, Frankfurt, Germany) containing 20 mg/ ml 1,4-diazabicyclooctane (Sigma Diagnostics). Confocal microscopy was performed with a Zeiss microscope equipped with LSM 510 software (Zeiss).
Progenitor cell cultures. BM MNCs from AA patients and normal controls (2 Â 10 5 and 2 Â 10 4 cells respectively) were cultured in IMDM containing 10% fetal calf serum (FCS), 380 mg/ml iron-saturated human transferrin, 1% BSA, 100 ng/ml flt3 ligand (flt3L; Immunex, Seattle, WA, USA), and stem cell factor (SCF; Amgen, Thousand Oaks, CA, USA), and in the absence or presence of caspase inhibitors zVAD and DEVD used at 10 mmol/l (Calbiochem, La Jolla, CA, USA). Cultures were maintained for 4 weeks with weekly half-medium changes. Harvested cells were counted and plated weekly into 1% methylcellulose cultures (Wodnar-Filipowicz et al, 1992) . Haemopoietic colonies derived from colony-forming units (CFUs) were counted under an inverted microscope after 14 d of culture.
Statistical analysis. FasL expression by AA and normal T cells, and colony growth of haemopoietic progenitors with and without caspase inhibitors, was compared with Student's unpaired t-test using StatView software (Abacus).
RESULTS

Elevated expression of intracellular FasL in T cells of AA patients
We measured the expression of FasL in T lymphocytes of q 2001 Blackwell Science Ltd, British Journal of Haematology 114: 884±890 patients with severe untreated AA. Using FACS analysis with the mAb NOK-1 that recognizes the extracellular domain of FasL, membrane-bound FasL was not detectable on the surface of CD3 1 cells in PB of healthy donors and of AA patients (Fig 1A) . Cell surface expression of FasL was observed when AA cells were stimulated with PMA and calcium ionophore in the presence of the metalloproteinase inhibitor BB3103 that prevented cleavage of FasL from the cell surface. FasL expression was also seen on the surface of cells from a patient with MDS (not shown). These results indicate that membrane-bound FasL can be measured with NOK-1 mAb after cell activation, but that it is not expressed by PB lymphocytes either in severe AA or healthy controls. As recent studies demonstrated that T cells contain FasL stored in secretory lysosomes (Bossi & Griffiths, 1999) , we analysed intracellular FasL in T lymphocytes permeabilized with saponin and subjected to flow cytometry. Levels of intracellular FasL detected with NOK-1 mAb were significantly higher in AA cells than in T cells from normal donors (Fig 1B) . A similar increase in intracellular FasL was also observed with a polyclonal antibody N20 directed against the cytoplasmic aminoterminal domain of FasL (not shown). Amounts of intracellular FasL, quantified as the mean fluorescence intensity (MFI), in eight patients with severe untreated AA were estimated as 8´7^1´4 (range 5´1± 17´2), which was significantly above the values of 4´6^0´4 (range 2´8±5´4) obtained in six healthy donors (Table I) . A comparison of the amount of FasL in T cells from PB and BM from individual patients always yielded similar results and no difference was observed between CD4 1 and CD8 1 T cells (not shown). One month after immunosuppressive treatment with ALG and CsA, intracellular FasL levels were lower (6´6^0´7) compared with samples from untreated AA patients (Table I) . However, the difference was not statistically significant, probably because of the early timepoint of analysis and the low number of patients analysed. As ALG and CsA prevent in vitro generation of PHA blasts expressing high levels of intracellular FasL (unpublished observations), further analysis of FasL expression with respect to the clinical development after immunosuppressive treatment is warranted.
To define the organellar localization of intracellular FasL, we performed an indirect immunofluorescence confocal microscopy with T cells purified from PB and stained with antibodies against FasL and cathepsin D, a hydrolase present in all lysosomal compartments. FasL-specific signals were observed in the cytoplasm of cells from healthy donors and AA patients using NOK-1 mAb (Fig 2A and B) , as well as N20 antibody (not shown). Although this immunofluorescence analysis was not quantitative, the intensity of signals obtained with AA cells appeared higher than with normal cells, in agreement with elevated FasL measured by FACS. FasL-specific signals overlapped to a large degree with cathepsin D signals (Fig 2C) , confirming the specificity of detection of cytoplasmic FasL and its localization in the lysosomal granules in T cells.
Expression of intracellular FasL in T cells of AA patients is increased by PHA
As activation of T cells is known to induce de novo synthesis of FasL, we incubated T cells for 3 d with PHA and measured intracellular FasL by FACS analysis. In a forward-/ side-scatter plot, two gates were set: a, representing the lymphocyte gate, and b, containing the PHA blasts (Fig 3A  and B) . All T cells freshly isolated from either normal or AA PB were present in gate a (not shown), while treatment with PHA resulted in the generation of lymphoblasts detectable in gate b. The proportion of blasts was significantly higher in AA than in normal samples (68´3% versus 29´2%), suggesting that T cells from AA are more susceptible to activation. Analysis of intracellular FasL using NOK-1 mAb demonstrated that the PHA blasts in gate b contained significantly higher levels of intracellular FasL than the residual non-activated cells in gate a (Fig 3C and D) . Thus, upon PHA stimulation, the majority of AA T cells progressed into an activated state characterized by high levels of intracellular FasL expression.
Caspase inhibitors enhance the survival of AA haemopoietic progenitors in vitro As susceptibility to Fas-mediated apoptosis may play a role in stem cell damage in AA, we tested whether growth of BM cells can be improved with caspase inhibitors which interrupt apoptotic pathways, including the Fas-mediated signalling. MNCs from BM of healthy donors and AA patients were cultured for 4 weeks in liquid medium supplemented with SCF and flt3L in the presence of DEVD and zVAD, inhibitors of the CPP32/caspase-3 and the ICE/ caspase-1 subfamilies respectively (Cohen, 1997) . The number of CFUs was evaluated by weekly plating aliquots of cells in methylcellulose cultures (Fig 4) . In cultures of cells from healthy donors, a 36-fold amplification of CFUs was observed until week 3, and DEVD and zVAD further enhanced their number by 2´2±fivefold (P , 0´05). In cultures of AA cells, both the duration of survival and the number of progenitors giving rise to CFUs was lower than in normal cultures, as expected (Marsh et al, 1990) . In the absence of caspase inhibitors, a 3´5-fold amplification of clonogenic progenitors was observed at week 1, but they were virtually exhausted on week 2. Addition of DEVD and zVAD resulted in a significantly increased survival of clonogenic CFUs; their numbers increased 9´8-fold (P , 0´05) at week 1 and even at week 2 corresponded to the number of CFUs used to initiate the liquid cultures. Although caspase inhibitors could not restore normal growth of AA cells, the results demonstrated that survival of AA progenitors could be improved by interrupting signalling pathways leading to apoptosis. 
DISCUSSION
We have demonstrated that T cells from patients with severe untreated AA contain about twofold higher levels of intracellular FasL than cells from healthy controls (P , 0´005). This increase was observed in both PB-and BMderived T cells. Moreover, AA cells were more susceptible to activation with PHA than normal cells and PHA-induced lymphoblasts contained large pools of intracellular FasL. These findings support the view that T lymphocytes are important effectors of haemopoietic damage in AA.
Although immune-mediated suppression of haemopoiesis is considered the most important mechanism in the development of idiopathic AA, understanding of the role of T cells in the pathogenesis of BM failure is elusive and potential autoantigens or target antigens of bacterial or viral origin remain unidentified (Young, 1996) . This is largely owing to the heterogeneity of the disease at presentation and the fact that many experimental findings on abnormalities in the T-cell compartment are not common to all AA patients (Maciejewski et al, 1994; Manz et al, 1997; Zeng et al, 1999) . Recent studies suggest that excess apoptosis may represent an important factor contributing to stem cell deficiency in AA. Expression of Fas receptor on BM-derived CD34
1 progenitors is increased compared with normal controls, and clonogenic AA progenitors show high sensitivity to anti-Fas-induced inhibition of colony formation in vitro (Maciejewski et al, 1995b) . However, the direct participation of T cells in Fasmediated killing of AA progenitors has never been demonstrated. We found no FasL expression on the surface of T cells freshly obtained from eight patients with newly diagnosed untreated severe AA. This is in accordance with previous reports that membrane-bound FasL on PB cells or soluble FasL in AA serum is not elevated (Callera et al, 1998; Hasegawa et al, 1998; Shinohara et al, 1999) . These results, in particular the failure to detect the membranebound ligand representing the functional FasL form, has made the significance of the FasL/Fas system in the pathogenesis of AA questionable.
We have now demonstrated that AA T cells contain higher levels of intracellular FasL than control T cells. The intracellular FasL in AA T cells co-localizes with cathepsin D, indicating that it is stored in the cytoplasmic lysosomal granules. Lysosome-specific storage of newly synthesized FasL occurs in CD4 1 and CD8 1 T cells (Bossi & Griffiths, 1999) ; accordingly, we found elevated intracellular FasL equally present in both subsets of AA T cells. The Fasdependent T cell-mediated cytotoxicity in AA may act when lymphocytes bearing intracellular FasL are activated by viral infections, cytokines or other stimuli, and release the prestored FasL locally in the BM. Expression of FasL on the cell surface is only transient, owing to susceptibility of the membrane-bound molecule to a rapid cleavage (Tanaka et al, 1998) . Indeed, upon treatment of AA cells with phorbol ester and ionomycin, we detected FasL on the surface of T cells; however, this was only when the metalloproteinase inhibitor BB3103 was present to prevent the proteolytic shedding. Low systemic levels of FasL in AA may thus be explained by brief cell surface expression and locally restricted release, possibly at concentrations below the limit of detection of the available FasL assays.
Intracellular storage and release of cytokines upon demand has emerged as a novel mechanism regulating the availability of biologically relevant molecules. CD40 ligand is stored in platelets and can be released within minutes upon activation (Henn et al, 1998) . As shown in our recent studies, flt3L is present intracellularly in T cells and is released to the cell surface in response to stem cell deficiency in AA (Chklovskaia et al, 1999; Pfister et al, 2000) . Intracellular FasL has been detected in lymphocytes (Martinez-Lorenzo et al, 1996; Bossi & Griffiths, 1999) , erythroid progenitor cells (Dai et al, 1998) and monocytes (Kiener et al, 1997) , and T cells contain also intracellular Fas receptor (Bennett et al, 1998) . Excess of intracellular cytokines may be a sign of immunopathology, as is the case of IFN-g detected using flow cytometry in permeabilized cells from AA patients (Sloand et al, 1997) , as well as IFN-g, interleukin 4 (IL-4) and IL-5 in patients with allergic reactions (Krouwels et al, 1997) . We have shown that T cells from AA patients are more susceptible to stimulation with PHA and the bulk of intracellular FasL is present in the activated lymphoblasts, suggestive of its pathological potential. The molecular mechanism leading to an increase in intracellular FasL levels in AA cells analysed ex vivo is not understood, but it may reflect an activated state of T cells upon antigen recognition in the BM.
Our preliminary observations in AA show that the in vivo levels of intracellular FasL during immunosuppression with CsA and ALG are lower than in untreated patients. This may represent one of the possible beneficial effects of immunosuppressive drugs in treatment of AA (Nissen et al, 1991) . The mechanism underlying the effect of CsA may involve inhibition of FasL mRNA expression (Dhein et al, 1995) , as well as inhibition of translocation of intracellular FasL to the cell surface (Toth et al, 1999) . The latter mechanism is reminiscent of the inhibitory effect of CsA on intracellular trafficking of a haemopoietic flt3L in human T lymphocytes (Chklovskaia et al, 2001) .
Severe stem cell deficiency is a hallmark of AA (Young, 1999) . In vitro, the colony-forming ability and the survival rate in suspension cultures of patients' BM is severely reduced, suggesting a functional defect of AA progenitors (Marsh et al, 1990; Wodnar-Filipowicz et al, 1992; Krieger et al, 1995) . We have shown that caspase inhibitors, zVAD and DEVD, increase the colony formation by AA marrow, but do not restore the normal growth, indicating that blocking the essential components of the apoptotic pathways cannot reverse the complex functional deficiency. However, caspases can be considered as targets for reducing apoptosis of haemopoietic progenitors in AA and other BM failure symptoms.
Taken together, our results on increased levels of intracellular FasL in T cells and improvement of AA progenitor cell growth by interrupting the caspase-mediated signalling cascade support an involvement of an apoptotic process in the pathophysiology of BM failure in AA. Understanding of the mechanism responsible for an increase in intracellular FasL in T lymphocytes and for triggering its release to the cell surface may help to elucidate the mechanism of haemopoietic suppression in AA.
